Online inquiry

IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3778MR)

This product GTTS-WQ3778MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CEACAM6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002483.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4680
UniProt ID P40199
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3778MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ444MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ8140MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ4404MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ5232MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ1133MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ2394MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ11998MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ1741MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW